Overview

Observational Program Neo-Penotran® Forte

Status:
Completed

Trial end date:
2015-04-01

Target enrollment:
0

Participant gender:
Female

Summary

Vaginitis is the most common gynecologic diagnosis in the primary care setting. In approximately 90 percent of affected women, this condition occurs secondary to bacterial vaginosis, vulvovaginal candidiasis, trichomoniasis or mixed infection. Neo-Penotran Forte is registered for treatment of these most common vaginal infections. Efficacy and safety of this product is already established, and this observational study was designed to learn more about practical use of Neo-Penotran® Forte in real life setting.

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Bayer

Treatments:

Metronidazole
Miconazole

Criteria

Inclusion Criteria:

- Patients older than 18 years with previously taken decision of their gynecologist to
prescribe Neo-Penotran Forte according to registered indications, and microbiological
tests were performed.

Exclusion Criteria:

- Presence of contraindications according to package insert.